Search
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16588ApprovedA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Categories: Inactivated Influenza A Virus VaccineSynonyms: Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated)Goldenseal
go.drugbank.com/drugs/DB16594ApprovedCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsStreptococcus pneumoniae type 6a capsular polysaccharide antigen
go.drugbank.com/drugs/DB16609ApprovedInvestigationalMixtures: SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (SINGLE DOSE - 1 DOSE), SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (MULTIDOSE - 5 DOSE)Tyrosinase
go.drugbank.com/drugs/DB16626InvestigationalTyrosinase is a multi-copper-containing multifunctional metalloenzyme with 4 possible oxidation states. … as melanogenesis).
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnMelphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.
OPB-111077
go.drugbank.com/drugs/DB16630InvestigationalOPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.
Glyceryl laurate
go.drugbank.com/drugs/DB16635InvestigationalCategories: Compounds used in a research, industrial, or household settingTeclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerImsidolimab
go.drugbank.com/drugs/DB16658InvestigationalImsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).
Etokimab
go.drugbank.com/drugs/DB16661InvestigationalEtokimab is under investigation in clinical trial NCT03614923 (Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)).